CHI's 3rd Annual High-Concentration Protein Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CHI's 3rd Annual High-Concentration Protein Formulations

Description:

At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high protein concentration formulations results in several manufacturing, stability, analytical, and delivery challenges. Thus, development of formulations for protein drugs requiring high dosing requires specific strategies. This popular annual conference will feature informative, high quality case studies and successful strategies to overcome the problems you are facing in the rapidly changing biotherapeutic landscape. 

Date: August 20, 2014 - August 21, 2014 
Location: Boston, MA USA
Venue: Renaissance Waterfront Hotel
Registration URL: https://chidb.com/register/2014/bpd/reg.asp
 
Contact Info: Nandini Kashyap

Phone: 781-972-5406
Website: www.bioprocessingsummit.com/Protein-Formulations
 

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search

At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high protein concentration formulations results in several manufacturing, stability, analytical, and delivery challenges. Thus, development of formulations for protein drugs requiring high dosing requires specific strategies. This popular annual conference will feature informative, high quality case studies and successful strategies to overcome the problems you are facing in the rapidly changing biotherapeutic landscape. 

Click here